EXTX — Exact Therapeutics AS Balance Sheet
0.000.00%
- NOK125.89m
- NOK67.74m
Annual balance sheet for Exact Therapeutics AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 159 | 104 | 69.4 | 46.4 | 99.5 |
| Net Total Receivables | 5.99 | 7.61 | 8.14 | 9.47 | 33.7 |
| Total Other Current Assets | |||||
| Total Current Assets | 166 | 111 | 77.5 | 55.9 | 133 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 4.52 | 6.33 | 4.97 | 5.42 | 4.81 |
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 170 | 118 | 82.5 | 61.3 | 153 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 10.6 | 10.5 | 16.1 | 15.5 | 37.6 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.6 | 11.9 | 17.4 | 16.2 | 37.7 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 160 | 106 | 65.1 | 45.1 | 116 |
| Total Liabilities & Shareholders' Equity | 170 | 118 | 82.5 | 61.3 | 153 |
| Total Common Shares Outstanding |